Genetics of inflammatory bowel disease: The role of the HLA complex

Tariq Ahmad, Sara E Marshall, Derek Jewell

Abstract

The human leucocyte antigen (HLA) complex on chromosome 6p21.3 is the most extensively studied genetic region in Inflammatory bowel disease (IBD). Consistent evidence of linkage to IBD3 (6p21.1-23), an area which encompasses the HLA complex, has been demonstrated for both Crohn’s disease and ulcerative colitis, and a number of replicated associations with disease susceptibility and phenotype have recently emerged. However, despite these efforts the HLA susceptibility gene(s) for IBD remain elusive, a consequence of strong linkage disequilibrium, extensive polymorphism and high gene density across this region. This article reviews current knowledge of the role of HLA complex genes in IBD susceptibility and phenotype, and discusses the factors currently limiting the translation of this knowledge to clinical practice.

© 2006 The WJG Press. All rights reserved.

Key words: Inflammatory bowel disease; Human leucocyte antigen complex; Crohn's disease; Ulcerative colitis; Genetics

Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: The role of the HLA complex. World J Gastroenterol 2006; 12(23): 3628-3635

http://www.wjgnet.com/1007-9327/12/3628.asp

INTRODUCTION

The human leucocyte antigen (HLA) complex is a highly polymorphic, gene dense region on chromosome 6p21.3 (Figure 1). The complex spans ~4 Mb and encompasses at least 130 expressed genes[1,2]. These include the highly polymorphic classical class I and II HLA genes essential for normal lymphocyte function, and a number of other genes with immunoregulatory function. Since the first report of an HLA association with IBD in 1972[3], more than 100 studies have been published investigating the role of HLA genes in determining susceptibility and phenotype of inflammatory bowel disease (IBD). Early data derived from both association and linkage analyses were inconsistent, reflecting the difficulties of inadequate sample size, low resolution typing techniques, poor statistical methodology and a failure to consider disease heterogeneity. However, since the mid-1990’s, advances in genotyping and computational technology, combined with improved study design, have been successfully applied to much larger, more accurately characterised cohorts of patients, and this has revealed important clues to molecular pathogenesis of IBD.

Genome-wide scans have shown consistent evidence of linkage to IBD3 (6p21.1-23), an area which encompasses the HLA complex. This has been demonstrated in several independent studies of both Crohn’s disease[4-8] and ulcerative colitis[8-9], and was recently confirmed by the IBD Consortium in a large replication study of 733 nuclear families[10]. The importance of this area was further highlighted by a meta-analysis of 10 published genome-wide scans[10]. Notably in this study, IBD3 was the only locus that met genome-wide significance, and provided stronger evidence of linkage than 16p13.1-16q12.2 (IBD1), the locus that contains the susceptibility gene CARD15. Although it is difficult to estimate the importance of this region in determining overall genetic susceptibility, calculations derived from studies of HLA allele sharing within families suggest that this region contributes between 10%-33% of the total genetic risk of Crohn’s disease[11] and 64%-100% of the total genetic risk of ulcerative colitis[12].

Interest in the HLA complex in IBD has traditionally focused on association with the classical class II HLA alleles, but recent insights into the biological function of other genes encoded within this region have led investigators to a more diverse exploration of this region.

CLASSICAL HLA CLASS II GENES

The classical class II HLA genes encode cell-surface...
glycoproteins which are expressed on antigen presenting cells, including dendritic cells and macrophages. Their major role is to present peptides to T cell receptors, as a prelude to T cell activation. There are three types of HLA Class II molecules expressed by a single cell, namely HLA-DR, HLA-DQ and HLA-DP. These are each made up of αβ heterodimers: the β chains are encoded by the DRB1, DQB1 and DPB1 genes respectively, all of which are highly polymorphic. The α chains for DPA and DQA are also highly polymorphic, while the DRA gene is invariant. In addition, gene duplication events have occurred on certain haplotypes producing additional DRB3, 4 and 5 genes. When present, these are expressed at low levels in conjunction with the DRA chain.

The mechanism by which classical HLA class II genes exert their influence in IBD is unclear, although a number of hypotheses have been postulated. Polymorphism in these molecules is concentrated around specific pockets of the binding groove that interact with critical side-chains or ‘anchor’ residues of a peptide. Thus different HLA molecules may bind preferentially to different peptides, or bind the same peptide with varying affinity. In IBD, cross reactivity (known as "molecular mimicry") may exist between the peptides derived from bacterial luminal flora and from self antigens present in the gut. This may lead to the generation of auto reactive T cells which contribute to disease pathogenesis through either stimulation or inhibition of the immune system. This mechanism is supported by identification of murine MHC-restricted CD4+ T cells reactive to enteric bacterial antigens that are able to induce colitis by adoptive transfer.

HLA-DRB1 is the most extensively studied gene in IBD. Convincing evidence of association has been described for a number of alleles, some of which confer

Figure 1 Crohn's disease map of chromosome 6p and the HLA region. The IBD susceptibility locus IBD3 is here defined by a 34cM chromosomal bin (6.2), which reached genome wide significance for IBD in the genome scan meta-analysis of van Heel et al. The IBD3 region encompasses the ~4MB HLA region shown in detail on the right of the figure. White, grey, striped and black boxes show expressed genes, gene candidates, non-coding genes and pseudogenes, respectively. Genes with polymorphisms associate with IBD are shown in red. Modified with permission from Shiina et al.
risk, whilst others are protective. Many of these were highlighted in a 1999 meta-analysis of 29 association studies published between 1966 and 1998[14]. Since publication of this report, more detailed genotype-phenotype analyses of this locus have been conducted in larger, accurately characterised, patient cohorts leading to the realisation that genetic variation within this region may explain some of the disease heterogeneity of IBD. The most consistently replicated associations are described below:

**HLA CLASS II ASSOCIATIONS WITH CROHN’S DISEASE**

**HLA-DRB1*07 and CARD15 negative ileal Crohn’s disease**

The most consistently replicated association of Crohn’s disease with a common HLA allele is with HLA-DRB1*07. The population frequency of this allele varies between 5%-29% in Europeans and North Americans but is less than 1% in Japanese. The 1998 meta-analysis demonstrated a weak association of HLA-DRB1*07 in unselected patients with Crohn’s disease (OR 1.42, CI 1.16-1.74)[14], but three subsequent studies of well-characterised patients from the UK (n = 244)[15,16], Canada (n = 432)[17] and Spain (n = 210)[18] showed that this association is specifically with patients with ileal involvement (with or without colonic disease). When comparison was made in these 3 studies between patients with, and patients without ileal disease, the Odd's Ratios for ileal disease were 1.5[15,17], 1.9[16] and 2.6[18] respectively, which are equivalent to those observed for possession of a single CARD15 variant. Importantly the UK and Canadian studies provided evidence for genetic heterogeneity in ileal Crohn’s disease, by demonstrating that the association with HLA-DRB1*07 is only present in patients who do not possess one of the three common Crohn’s disease associated CARD15 variants[15,16].

Studies in other ethnic groups have not been as detailed. Few Jewish patients were included in the UK or Spanish studies, but data from the Canadian study suggested that this phenotypic association may also be present in this ethnic group, although the relatively small number included prevented this reaching statistical significance[16]. DRB1*07 appears not to be associated with Crohn’s disease in the Japanese, although studies have been insufficiently powered to detect a modest effect of such a rare allele.

**HLA-DRB1*0103 and Colonic Crohn’s disease**

HLA-DRB1*0103 is a rare allele with a frequency of less than 2% in European and white North American populations. It is present at a similar frequency in Jews but is absent in the Japanese. A strong association of HLA-DRB1*0103 with ulcerative colitis was identified in 1996[12] but not demonstrated in Crohn's disease until 2000[18], almost certainly a consequence of the disease heterogeneity of Crohn's disease and the low prevalence of this allele. This association has been widely replicated since, although studies in Jewish patients have been inconsistent[16,18]. Association with this allele is observed both on the DRB1*0103-DQB1*0301 and DRB1*0103-DQB1*0501 haplotypes, strongly implicating DRB1*0103 in disease pathogenesis. It is now clear that DRB1*0103 is strongly associated with colonic location, particularly isolated colonic disease[15,17,19]. The Odd's ratios for isolated colonic disease range from 5.1 to 18.5 in non-Jewish caucasoids[16-17]. Data from a recent study suggests that amongst British patients with isolated colonic Crohn’s disease, DRB1*0103 is associated with the development of severe disease as defined by the requirement for infliximab or colectomy. Furthermore data from this study suggests this allele may predict time to surgery (personal communication-Laura Hancock). Despite the strength of these associations it should be noted that this allele was present in no more than 32% of patients with isolated colonic disease, indicating that whilst this marker has a high positive likelihood ratio, the negative likelihood ratio limits its clinical application. Association with perianal location and fistulizing behaviour, reported in two studies, probably reflects their clinical association with colonic disease, rather than an independent genetic association[15,17].

**HLA-DRB3*0301 - HLA-DRB1*1302**

The HLA-DRB3 gene is expressed in less than 50% of Europeans and white North Americans, and has not been extensively studied in IBD. However, a meta-analysis of three studies, each comprising less than 70 patients, supports a positive association of Crohn’s disease with DRB3*0301 (OR 2.18, CI 1.25-3.80)[14]. This association has been replicated in a larger cohort of British patients (RR = 2.4)[15], although once again inadequate sample size has prevented investigators determining whether it is due to linkage disequilibrium with another disease associated DRB1 allele, DRB1*1302[16], or the HLA class I allele Cw*0802[19]. Although stratification by disease phenotype is limited, data from this latter study, which awaits replication, suggests that this association is most marked in patients with perianal disease.

**HLA-DRB1*04 and CARD15 positive ileal disease?**

Data from the meta-analysis of seven small studies also demonstrated a non-significant increase in the common allele HLA-DRB1*04 in Crohn’s disease (OR 1.62 CI 0.73-3.61)[14]. This association is particularly important in Japanese cohorts, in whom the strongest HLA associations are with DRB1*0405, *0410, and the linked DQB1*0401, 0402 alleles[20-22]. Association with DRB1*04 has not been widely observed in European and North American patients. However in the recent Canadian study, a weak association with DRB1*04 was identified in patients with ileal disease RR = 1.7 (1.1-2.5)[16]. It is interesting that this association was stronger in patients possessing one of the three common Crohn’s disease associated CARD15 variants, which may indicate an epistatic interaction between this DRB1 allele and CARD15 in determining susceptibility to ileal Crohn’s disease[14]. Genotype-phenotype analysis of this allele in the Japanese is awaited.

**HLA-DRB1*1501 – Crohn’s disease protection**

Much confusion has surrounded associations of Crohn’s disease with the serologically defined HLA allele DR2. DR2 includes the molecularly defined alleles HLA-DRB1*1501 and HLA-DRB1*1502, amongst others. The
allele frequency of DRB1*1501 varies between 6%-25% in European and white North American populations and 6%-10% in the Japanese. It is negatively associated with Crohn's disease which explains the earlier negative association reported with the serological antigen DR2 (OR 0.83, CI 0.70-0.9) highlighted in the 1999 meta-analysis. This allele appears to confer protection against all subgroups of Crohn's disease, in all ethnic groups including Japanese.

**HLA CLASS II ASSOCIATIONS WITH ULCE-\nRATIVE COLITIS**

**HLA-DRB1*0103 and severe, extensive ulcerative colitis**
The most consistently replicated association of ulcerative colitis in European and American populations is with the rare allele HLA-DRB1*0103. Data from the Stokkers et al. meta-analysis, derived from only 3 studies, demonstrated a moderate association in unselected ulcerative colitis patients (OR 3.42 CI 1.52-7.69). Subsequent larger studies have confirmed this association in Spanish, North American, British, and Mexican cohorts. This association is particularly strong in patients with extensive or severe disease, as defined by the need for colectomy for failed medical therapy. Amongst patients who require colectomy this allele may also be associated with a shorter mean time to surgery. Once again, the frequency of this allele, even in the ulcerative colitis population, is too low to be clinically useful in predicting disease course.

**HLA-DRB1*1502**
HLA-DRB1*1502 is associated with ulcerative colitis in European, North American, Japanese, and Korean populations. Although the background prevalence of this varies considerably, being highest in the Japanese (20%-25%) and lowest in Northern Europeans (less than 1%), the associated relative risk is similar in all populations (2-4.5). This interesting transracial concordance suggests this allele, or a nearby allele, is a true disease causing variant. This association is specifically with HLA-DRB1*1502, rather than HLA-DRB1*1501, and explains the earlier reported association with the serological antigen DR2 (OR 2.00, CI 1.52-2.63) highlighted in the 1999 meta-analysis. These two alleles differ only at amino acid position 86 within pocket 1 of the peptide binding groove. At this position HLA-DRB1*1501 has a valine and DR1*1502 (and DRB1*0103) a glycine. Limited data suggests HLA-DRB1*1502 is associated with extensive and intractable ulcerative colitis amongst Japanese, but not Korean patients.

In Japanese and British UC patients association has also been reported with HLA-B*52, the class I allele found in linkage disequilibrium with HLA-DRB1*1502. However, studies have been insufficiently powered to determine which allele represents the primary association due to the highly conserved nature of this haplotype. Interestingly HLA-B*52, but not HLA-DRB1*1502, has also been shown to be associated with colonic Crohn's disease in these populations, providing further evidence of a shared genetic basis for ulcerative colitis and colonic Crohn's disease.

**HLA-DRB1*04-ulcerative colitis protection**
The common HLA-DRB1*04 allele is negatively associated with ulcerative colitis in Northern Europeans and Japanese populations, in contrast to the positive association in Crohn's disease. Data from the Stokkers meta-analysis of 15 studies demonstrated an Odd's Ratio of 0.54 (CI 0.73-3.61) in ulcerative colitis. In the British population, the protective effect of this allele is confined to the most prevalent subtype DRB1*0401, and only then, when present on the two locus haplotype DRB1*0401-DQB1*0301. This suggests that either an interaction between DRB1*0401 and DQB1*0301 is important for disease protection, or, and perhaps more likely, that the true protective polymorphism is found nearby on the associated extended haplotype.

**HLA CLASS II ASSOCIATIONS WITH THE EXTRA-INTESTINAL MANIFESTATIONS**
A number of HLA associations have been described with the extra-intestinal manifestations of IBD. The majority of data has been derived from small studies from one single centre and should be interpreted with caution until replicated. Small sample size has also hindered attempts at determining the primary association, but the most convincing associations have been described with DRB1*0103 in mixed studies of ulcerative colitis and Crohn's disease. Type 1 peripheral arthritis, a migratory pauciarticular large joint arthritis has specifically been shown to be associated with HLA-DRB1*0103, as well as the class I alleles that may be found in linkage disequilibrium, namely B*27 and B*35. In this study, HLA-DRB1*0103 was found in 35% of patients compared to 3% of controls. In patients with recurrent arthritis this association becomes even stronger, being found in 65% of patients. In contrast, type II peripheral arthritis, a chronic, small joint, symmetrical arthritis is associated with HLA-B*44. Uveitis has also been associated with DRB1*0103 and HLA-B*27, and erythema nodosum with the TNF promoter SNP TNF-1031C. However, it is important to note that an increased prevalence of extra-intestinal manifestations has previously been reported in patients with colonic Crohn's disease raising the possibility that the association between DRB1*0103 and the extra-intestinal manifestations may merely reflect the replicated association with colonic disease. Further work is required to clarify this issue.

**OBSERVATIONS ON HLA CLASS II ASSO-\nCIATIONS WITH IBD**
A number of important observations should be noted from the reported associations with HLA Class II alleles described above. Firstly, the specific associations with Crohn's disease and ulcerative colitis are different, with the notable exceptions of the shared association with HLA-DRB1*0103.
of ulcerative colitis and colonic Crohn's disease with HLA-DRB1*0103 and HLA-B*52. Secondly it is clear that multiple alleles, rather than a single allele, may be associated with any specific phenotype. Whilst these associations may merely reflect linkage disequilibrium with a nearby gene, this observation supports peptide presentation as an explanation for these associations, and raises the possibility of a shared disease-associated epitope, as seen in rheumatoid arthritis. Some associated class II alleles do indeed share significant residue changes in the third hypervariable region, which forms part of the antigen binding domain. However these are not shared by all of the associated alleles, suggesting this hypothesis cannot entirely explain these associations. Thirdly, it is not known whether a gene dose effect operates, such that possession of two HLA risk alleles confers additional risk. To date studies in IBD have not been sufficiently powered to conclusively answer this question. Fourthly, whilst many of the associations appear to be robust, it is clear that the penetrance of the genotype is low, and the presence of a risk allele is neither necessary nor sufficient for disease to occur. Finally the reported associations vary with ethnicity and geographical location, reflecting genetic heterogeneity, prevalence of risk alleles in the background population, and population specific patterns of linkage disequilibrium across the HLA. This illustrates the importance of studying ethnically homogenous cohorts in order to prevent population stratification.

**OTHER IBD GENES IN THE HLA COMPLEX**

In IBD, as with a number of other HLA Class II-associated diseases, there is increasing evidence for more than one susceptibility locus within the HLA complex. The evidence is accumulating faster for Crohn's disease than ulcerative colitis, reflecting the focus of recent research efforts towards Crohn's disease. Such a gene(s) might act independently of the class II locus, or interact with disease associated class II alleles on either the cis or trans chromosome. However, the presence of highly conserved haplotypes across such a gene-dense region has made it extremely difficult to dissect out primary associations. In Crohn's disease, it is most likely that a second disease-susceptibility locus is located between the telomeric end of class I, and the central class III regions. Specific associations have been identified with the class I genes HLA-B and Cw, the non-classical MHC class I-related (MIC) genes, MICA and MICB, and the three heat shock protein genes (HSPA1L, HSPA1A, HSPA1B). However most recent interest has focused on a cluster of immunoregulatory genes centred in the HLA class III region, including TNF, LTA, LTB, NFκBIL and BAT1. To date most studies have investigated only a few SNPs in a single gene, chosen because of previously described associations, or for ease of genotyping, rather than their ability to 'tag' a haplotype to comprehensively survey the linkage disequilibrium across the gene. Results have generally been inconsistent, even within phenotypically defined subgroups, and as with other HLA associated diseases, very few studies have fully controlled for linkage disequilibrium with HLA-DRB1. Associations with TNF and the MIC genes are now discussed.

**TNF**

The most widely studied gene in the HLA class III region is TNF, which encodes a proinflammatory cytokine that is found in increased concentrations in the mucosa, serum and stool of patients with IBD. The ΔARE and TNF-α mice models provide experimental evidence of the importance of TNF in IBD, and convincing clinical evidence is seen in both Crohn's disease and ulcerative colitis from the dramatic response following infusion of the anti-TNFα monoclonal antibody, infliximab. A large number of TNF promoter polymorphisms have been described, raising the possibility that altered TNF expression may play a role in determining susceptibility to IBD. However the functional significance of individual polymorphisms remains uncertain as TNF regulation is highly cell and context-specific and currently available in vitro systems provide limited insight into how TNF is regulated in vivo.

The most consistent TNF association is with the -857C allele. This is a very common allele: 99% of the healthy caucasoid population possess at least one copy and -85% are homozygote. A modest association with the -857C allele genotype was reported in TDT and case-control analyses from the UK. Relative risks for the homozygote TNF-857CC genotype were 2.4 (CI 1.4–4.0) in ulcerative colitis and 2.4 (CI 1.4–4.2) in Crohn's disease patients lacking the three associated CARD15 variants. This association was replicated in a TDT study from Australia, but unlike the British study, evidence for epistasis was observed between TNF-857C and CARD15 variants. Further evidence for an epistatic interaction was noted in a recent large TDT study from the IBD consortium, in which the TNF-857C allele was shown to be associated with Crohn's disease, but only in CARD15 transmitting families. No association was found in ulcerative colitis, possibly a consequence of the smaller number of ulcerative colitis families included. At present the TNF-857CC genotype has not been found to be associated with a specific Crohn's disease or ulcerative colitis phenotype. An important confounder, which has not been directly investigated by either of these studies, is that the rare, protective -857T allele is the linkage disequilibrium with DRB1*0301, an allele shown by several studies to confer protection to Crohn's disease. Thus it is possible that the TNF-857C association simply reflects linkage disequilibrium within this highly complex region.

Modest associations have also been reported with many other polymorphic sites in the TNF promoter. In Crohn's disease these include TNF-1031C [37-41], TNF-863A [42] and TNF-308A [43]. The association with TNF-308A appears to be specifically associated with colonic Crohn's disease (with or without colonic disease) [15,49,50], however once again this finding is confounded by the tight linkage disequilibrium across the A1-B8-DR3 ancestral haplotype, the only common haplotype to contain the TNF-308A allele. In small studies TNF-308A has also been shown to be associated with ulcerative colitis [41,52] providing further evidence of shared genetic susceptibility for ulcerative colitis and colonic Crohn's disease. TNF promoter
polymorphisms may also predict ulcerative colitis phenotype: In a British study, which requires replication, homozygosity for a common promoter haplotype, defined by the common alleles at each of 6 positions, were more likely to have distal disease that remained distal throughout the period of follow-up.

**MICA and MICB**

The non-classical MHC class I-related (MIC) genes, MICA and MICB, are expressed on the basolateral cell surface of the gastrointestinal epithelium as well as fibroblasts, endothelial cells and dendritic cells. Their expression is markedly increased in response to cellular stress including both viral and bacterial infection. MICA and MICB bind to an activating receptor NKG2D, which is expressed on NK cells, CD8 αβ T cells, γδ T cells and activated macrophages. Interaction between these receptors may directly stimulate cell cytotoxicity as well as providing costimulation for NK and T cell activation.

Exons 2, 3 and 4 of MICA and MICB are highly polymorphic, and 54 MICA alleles have been officially designated to date. The functional significance of these polymorphisms and the nature of selective forces maintaining them are not known, but the presence of a high proportion of non-synonymous substitutions suggests that these polymorphisms are not the result of random mutation alone. Importantly, several MICA alleles have been shown to alter the binding affinity with NKG2D by as much as 30 fold, suggesting they might exert a functional effect on immune activation. Studies involving unselected IBD cohorts from Europe have failed to report consistent associations with MICA or MICB polymorphisms. However, in the Japanese, a consistent association has been reported with MICA-A6 and UC, although this does not appear to be independent of the association with the adjacent HLA-B52 allele. In a phenotypically characterised cohort from the UK, MICA*010 and B*1501, which are in linkage disequilibrium, were shown to be associated with perianal Crohn's disease (RR = 2.1), a finding which requires confirmation.

**DOES HLA DETERMINATION HAVE A ROLE IN CLINICAL PRACTICE?**

Clinical observation, supported by molecular and serological data, strongly suggests that IBD is a heterogeneous family of inflammatory disorders. Ultimately, it is hoped that more accurate clinical, serological and molecular definition of these disorders will lead to better understanding of the different biological mechanisms and complex environmental interactions specific to disease subgroups. This would assist clinicians in the prediction of disease course, prognosis, complications and response to therapy. The data reviewed in this report demonstrate that genes in the HLA are important in determining susceptibility and phenotype of Crohn's disease and ulcerative colitis. Although the specific disease causing gene(s) remain unidentified, the strength and consistency of the emerging HLA associations have confirmed the importance of classifying patients both by accurately defined clinical characteristics, and by possession of known genetic risk factors, such as CARD15 disease associated variants.

In both Crohn's disease and ulcerative colitis, the most consistently replicated associations are with the classical class II gene, HLA-DR. In Crohn's disease the strongest associations are observed with subgroups defined by location of disease. No consistent associations have been reported with disease behaviour, a less stable phenotypic characteristic, or with age at diagnosis. At present, there is little information about HLA associations with complications or response to treatment in Crohn's disease. In ulcerative colitis, the strongest HLA associations are seen with overall susceptibility, which is consistently associated with two alleles, DRB1*0103 and DRB1*1502. These alleles vary widely in prevalence across ethnic groups. Fewer subgroup associations have been identified than with Crohn's disease, but the association with DRB1*0103 is particularly strong in patients with extensive or severe disease. However, the low sensitivity and specificity of these associations currently preclude their use as a tool in diagnosis of either Crohn's disease or ulcerative colitis. For the same reason, it is unlikely that the use of HLA markers alone will be useful in disease screening of asymptomatic, genetically high risk individuals.

In addition to the interest in using biomarkers to predict IBD susceptibility, there is also considerable interest in using molecular and serological markers to assist in the discrimination of Crohn's disease from ulcerative colitis. Currently, markers in the HLA cannot be reliably used for this purpose. Indeed the shared association of DRB1*0103 and B*52 with ulcerative colitis and colonic Crohn's disease suggests the presence of at least one shared HLA susceptibility factor, providing a tantalising clue as to the potential molecular basis for the definition of colonic inflammation. Such shared HLA factors may explain in part why both forms of IBD can coexist in a family at a frequency greater than expected by chance. The apparent differential effect of HLA-DRB1*0401, which is a susceptibility allele in Crohn's disease and a protective allele in ulcerative colitis is interesting, but weak, population specific, and neither sufficiently sensitive or specific to be clinically useful.

In the near future, knowledge of an individual's HLA genotype is likely to be most useful in the prediction of disease course in patients with an established diagnosis of Crohn's disease or ulcerative colitis. However, at present, the sensitivity and specificity of even the most robust associations limit their application in isolation in this clinical context. Integration of an individual's HLA genotype into a panel of other genetic and serological markers may improve the sensitivity and specificity, although ultimately this is likely to require the identification of the primary IBD genes within this complex region.

In common with virtually all other HLA associated complex diseases, the HLA susceptibility gene(s) for IBD remain elusive. This is a consequence of the obstacles that challenge the mapping of disease genes within this region, including the high gene density and degree of polymorphism; the complex haplotype structure and
patterns of linkage disequilibrium; the relatively small relative risks conferred by disease associated alleles; and the likely clustering of more than one IBD susceptibility gene, either within the HLA, or within the surrounding IBDS locus.

REFERENCES

1. Complete sequence and gene map of a human major histo-compatibility complex. The MHC sequencing consortium. Nature 1999; 401: 921-923

2. Shinya T, Tamiya G, Oka A, Takishima N, Yamagata T, Kikkawa E, Iwata K, Tomizawa M, Okuaki N, Kuwano Y, Watanabe K, Fukuuzumi Y, Hakura S, Sugawara C, One A, Yamazaki M, Tashiro H, Ando A, Ikemura T, Soeda E, Kimura M, Bahram S, Inoko H. Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci U S A 1999; 96: 13282-13287

3. Gleeson MH, Walker JS, Wentzel J, Chapman JA, Harris R. Human leucocyte antigens in Crohn's disease and ulcerative colitis. Gut 1972; 13: 438-440

4. Ma Y, Olmen JD, Li Z, Bentley LG, McElree C, Pressman S, Targan SR, Fischel-Ghodsian N, Rotter JJ, Yang H. A genomewide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999; 5: 271-278

5. Hame P, Schreiber S, Shaw SH, Lau KF, Bridger S, Macpherson AJ, Cardon LR, Sakul H, Harris TJ, Buckler A, Hall J, Stokkers P, Van Deventer SJ, Nürnberg P, Mirza MM, Lee JC, Lennard-Jones JE, Mathew CG, Curran ME. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999; 64: 808-816

6. Hame P, Shaw SH, Saiz R, Leyens N, Lantermann A, Mascheretti L, Lynch NJ, Macpherson AJ, Bridger S, van Deventer S, Stokkers P, Morin P, Mirza MM, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999; 65: 1647-1655

7. Rioux JD, Silverberg MS, Daly MJ, Steinhardt AH, McLeod RS, Griffiths AM, Green T, Brettin TS, Stone V, Bull SB, Bitton A, Williams CN, Greenberg GR, Cohen Z, Lander ES, Hudson TJ, Siminovich KA. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66: 1863-1870

8. Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Williams CN, Greenberg GR, Cohen Z, Wade JA, Siminovich KA. A population-and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 1-9

9. Matake H, Okabe N, Naito S, Yatou T. An HLA study on 149 Japanese patients with Crohn's disease. Gastroenterol Jpn 1992; 27: 496-501

10. Nakajima A, Matsuhashi N, Kodama T, Yakuza Y, Takazoe M, Kimura A. HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology 1995; 109: 1462-1467

11. Yoshitake S, Kimura A, Okada M, Yato T, Sasazuki T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 1996; 53: 350-358

12. de la Concha EG, Fernandez-Arquero M, Martinez A, Vigil P, Vidal F, Lopez-Nava G, Diaz-Rubio M, Garcia-Paredes J. Amino acid polymorphism at position 71 in HLA-DR beta chain plays a critical role in susceptibility to ulcerative colitis. Dig Dis Sci 1999; 44: 2324-2329

13. Ahmad T, Armuzzi A, Neville M, Buncic M, Ling KL, Welsh K, Marshall SE, Jewell DP. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003; 62: 527-535

14. Yamamoto-Furuhashi JK, Uscanga LF, Vargas-Alarcón G, Ruiz-Morales JA, Higueria L, Cúthino T, Rodríguez-Pérez JM, Villarreal-Garza C, Granados J. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 2003; 64: 119-123

15. Roussoumoustakaki M, Satsangi J, Welsh K, Lewis E, Fanning G, Targan S, Landers C, Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gut 1997; 112: 1845-1853

16. Bouna G, Cruisius JB, Garcia-Gonzalez MA, Meijer BU, Hellemans HP, Hakvoort RJ, Schreuder GM, Kostense PJ, Meuwissen SG, Peña AS. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999; 115: 294-300

17. Futami S, Aoyama N, Honsako Y, Tamura T, Morimoto S, Nakashima T, Ohmoto A, Okano H, Miyamoto M, Inaba H. HLA-DBB1*1502 allele, but not subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci 1995; 40: 814-818

18. Myung SJ, Yang SK, Jung HY, Chang HS, Park B, Hong WS, Kim JH, Min I. HLA-DRB1*1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study. Int J Colorectal Dis 2002; 17: 233-237

19. Masuda H, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994; 89: 1957-1962
Seki SS, Sugimura K, Ota M, Matsuzawa J, Katsuyama Y, Ishizuka K, Mochizuki T, Suzuki K, Yoneyama O, Mizuki N, Honma T, Inoko H, Asakura K. Stratification analysis of MICA triplet repeat polymorphisms and HLA antigens associated with ulcerative colitis in Japanese. *Tissue Antigens* 2001; 58: 71-76.

Kimouchi Y, Matsumoto K, Negoro K, Takagi S, Takahashi S, Hiwatashi N, Shimosegawa T. HLA-B phenotype in Japanese patients with Crohn's disease. *Dis Colon Rectum* 2003; 46: S10-S14.

**Orchard TR**, Thiagaraja S, Welsh KL, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. *Gastroenterology* 2000; 118: 274-278.

**Orchard TR**, Chua CN, Ahmad T, Cheng H, Welsh KL, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. *Gastroenterology* 2002; 123: 714-718.

**Rankin GB**, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. *Gastroenterology* 1979; 77: 914-920.

**Gregersen PK**, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum* 1987; 30: 1205-1213.

**Newton J**, Brown MA, Milicic A, Ackerman H, Darke C, Wilson JN, Wordsworth BP, Kwiatkowski D. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotixin alpha-tumor necrosis factor haplotype. *Arthritis Rheum* 2003; 48: 90-96.

de la Concha EG, Fernández-Arquero M, Vigil P, Rubio A, Maluenda C, Polanco I, Fernandez C, Figueredo MA. Celiac disease and TNF promoter polymorphisms. *Hum Immunol* 2000; 61: 513-517.

**Fernandez-Arquero M**, Arroyo R, Rubio A, Martin C, Vigil P, Consejo L, Figueredo MA, de la Concha EG. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. *Neurology* 1999; 53: 1361-1363.

**Degli-Esposti MA**, Abraham LJ, McCann V, Spies T, Christiansen FT, Dawkins RL. Ancient haplotypes reveal the role of the central MHC in the immunogenetics of IDDM. *Immunogenetics* 1992; 36: 345-356.

**Nomura E**, Kimouchi Y, Negoro K, Kojima Y, Oomori S, Sugimura M, Hiroki M, Takagi S, Aihara H, Takahashi S, Hiwatashi N, Shimosegawa T. Mapping of a disease susceptibility locus in chromosome 6p in Japanese patients with ulcerative colitis. *Genes Immun* 2004; 5: 477-483.

**Kontoyianis D**, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. *Immunity* 1999; 10: 387-398.

**Neurath MF**, Fuss I, Pasparakis M, Alexopoulos L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. *Eur J Immunol* 1997; 27: 1743-1750.

**van Heel DA**, Udalova IA, De Silva AP, McGovern DP, Kniouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP, Kwiatkowski D. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kappaB transcription factors. *Hum Mol Genet* 2002; 11: 1281-1289.

**O'Callaghan NJ**, Adams KE, van Heel DA, Cavanaugh JA. Association of TNF-alpha-857C with inflammatory bowel disease in the Australian population. *Scand J Gastroenterol* 2003; 38: 533-534.

**Ahmad T**, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes K, Crawford J, Sato H, Ling KL, Barnardino M, Goldthorpe S, Walton R, Bunce M, Jewell DP, Welsh KL. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. *Hum Mol Genet* 2003; 12: 647-656.

**Negoro K**, Kimouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. *Gastroenterology* 1999; 117: 1062-1068.

**Levine A**, Karban A, Eliakim R, Shaoul R, Reif S, Pacht A, Ward J, Yakir B, Silver EL. A polymorphism in the TNF-alpha promoter gene is associated with pediatric onset and colonic location of Crohn's disease. *Am J Gastroenterol* 2005; 100: 407-413.

**Louis E**, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, Croes F, Dupont P, Davin L, Omri S, Rutgeerts P, Belaiche J. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? *Clin Exp Immunol* 2000; 119: 64-68.

**Ferreira AC**, Almeida S, Tavares M, Canedo P, Pereira F, Regalo G, Figueiredo C, Trindade E, Seruca R, Carneiro F, Amil J, Machado JC, Tavares-Veloso F. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. *Inflamm Bowel Dis* 2005; 11: 331-339.

**Bouma G**, Xia B, Crusius JB, Biocq G, Koutoubakis I, Von Blumberg BM, Meuwissen SG, Peña AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). *Clin Exp Immunol* 1996; 103: 391-396.

**Sashio H**, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, Fukui S, Sawada K, Fukuda Y, Tamura K, Satomi M, Shimoyama T, Furuyama J. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. *Immunogenetics* 2002; 53: 1020-1027.

**Das H**, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. *Immunity* 2001; 15: 83-93.

**Tieng V**, Le Bouguénec C, du Merle L, Bertheau P, Desrumaux P, Janin A, Charonn T, Doutbert A. Binding of Escherichia coli adhesin AafE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. *Proc Natl Acad Sci U S A* 2002; 99: 2977-2982.

**Diefenbach A**, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. *Nat Immunol* 2000; 1: 119-126.

**Bauer S**, Groh V, Wu J, Steine J, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 1999; 285: 727-729.

**Steinle A**, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. *Immunogenetics* 2001; 53: 279-287.

**Ahmad T**, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Barnardino M, Welsh KL, Jewell DP, Bunce M. High resolution MIC genotypotyping: design and application to the investigation of inflammatory bowel disease susceptibility. *Tissue Antigens* 2002; 60: 164-179.

**Glas J**, Martin K, Brunner G, Kopp R, Folwaczny C, Weiss EH, Albert ED. MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. *Tissue Antigens* 2001; 58: 243-249.

**Fdez-Morera JL**, Rodrigo L, López-Vázquez A, Rodero SR, Martínez-Borra J, Niño P, González S, López-Larrea C. MHC class I chain-related gene A transmembrane polymorphism modulates the extension of ulcerative colitis. *Hum Immunol* 2003; 64: 816-822.

**Shiina T**, Inoko H, Kulsik JK. An update of the HLA genomic region, locus information and disease associations 2004. *Tissue Antigens* 2004; 64: 631-649.